Literature DB >> 32616627

National trends in bowel and upper abdominal procedures in ovarian cancer surgery.

Joseph A Dottino1, Weiguo He2, Charlotte C Sun1, Hui Zhao2, Shuangshuang Fu2, Jose Alejandro Rauh-Hain1, Rudy S Suidan1, Karen H Lu1, Sharon H Giordano2, Larissa A Meyer3.   

Abstract

OBJECTIVES: In the United States, trends in the initial treatment approach for ovarian cancer reflect a shift in paradigm toward the increased use of neoadjuvant chemotherapy and interval cytoreductive surgery. The aim of this study was to evaluate the trends in surgical cytoreductive procedures in ovarian cancer patients who underwent either primary or interval cytoreductive surgery.
METHODS: This retrospective, population-based study examined patients with stage III/IV ovarian cancer diagnosed between January 2000 and December 2013 identified using SEER-Medicare. Small or large bowel resection, ostomy creation, and upper abdominal procedures were identified using relevant billing codes and compared over time. A 1:1 primary and interval cytoreductive propensity matched cohort was created using demographic and clinical variables. 30-day complications and the use of acute care services were compared.
RESULTS: A total of 5417 women were identified. 34% underwent bowel resections, 16% ostomy creation, and 8% upper abdominal procedures. There was an increase in bowel resections and upper abdominal procedures from 2000 to 2013 in patients who underwent primary cytoreductive surgery. Compared with patients who received primary cytoreduction, patients who underwent interval cytoreductive surgery were less likely to undergo bowel resection (OR=0.50; 95% CI [0.41, 0.61]) or ostomy creation (OR=0.48; 95% CI [0.42, 0.56]). Upper abdominal procedures did not differ between groups. For patients who underwent primary cytoreductive surgery, these procedures were associated with intensive care unit stay (4.6% vs <2%, P<0.01). In both primary and interval cytoreductive surgery patients, the receipt of bowel and upper abdominal procedures was associated with multiple 30-day postoperative complications and higher rates of readmission and emergency room visits.
CONCLUSIONS: The performance of upper abdominal procedures in ovarian cancer patients increased from 2000 to 2013. Interval cytoreductive surgery was associated with decreased likelihood of bowel surgery. In matched primary and interval cytoreductive surgery cohorts, the receipt of these procedures were associated with the increased likelihood of postoperative complications and use of acute care services. © IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  ovarian cancer; postoperative complications; surgery

Year:  2020        PMID: 32616627      PMCID: PMC8328049          DOI: 10.1136/ijgc-2020-001243

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  23 in total

1.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

Authors:  Sean Kehoe; Jane Hook; Matthew Nankivell; Gordon C Jayson; Henry Kitchener; Tito Lopes; David Luesley; Timothy Perren; Selina Bannoo; Monica Mascarenhas; Stephen Dobbs; Sharadah Essapen; Jeremy Twigg; Jonathan Herod; Glenn McCluggage; Mahesh Parmar; Ann-Marie Swart
Journal:  Lancet       Date:  2015-05-19       Impact factor: 79.321

2.  Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: Analysis and management of complications in upper abdominal surgery.

Authors:  Pierluigi Benedetti Panici; Violante Di Donato; Margherita Fischetti; Assunta Casorelli; Giorgia Perniola; Angela Musella; Claudia Marchetti; Innocenza Palaia; Pasquale Berloco; Ludovico Muzii
Journal:  Gynecol Oncol       Date:  2015-03-28       Impact factor: 5.482

3.  Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.

Authors:  Emily Hinchcliff; Alexander Melamed; Amy Bregar; Elisabeth Diver; Joel Clemmer; Marcela Del Carmen; John O Schorge; J Alejandro Rauh-Hain
Journal:  Gynecol Oncol       Date:  2017-11-08       Impact factor: 5.482

4.  Development of a comorbidity index using physician claims data.

Authors:  C N Klabunde; A L Potosky; J M Legler; J L Warren
Journal:  J Clin Epidemiol       Date:  2000-12       Impact factor: 6.437

5.  Predictors of extended intensive care unit resource utilization following surgery for ovarian cancer.

Authors:  Teresa P Díaz-Montes; Mariana L Zahurak; Robert E Bristow
Journal:  Gynecol Oncol       Date:  2007-08-31       Impact factor: 5.482

6.  Splenectomy as Part of Cytoreductive Surgery in Recurrent Epithelial Ovarian Cancer.

Authors:  Nicolae Bacalbasa; Irina Balescu; Simona Dima; Vladislav Brasoveanu; Irinel Popescu
Journal:  Anticancer Res       Date:  2015-09       Impact factor: 2.480

7.  Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  Gynecol Oncol       Date:  2016-08-08       Impact factor: 5.482

8.  Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.

Authors:  Dennis S Chi; Eric L Eisenhauer; Oliver Zivanovic; Yukio Sonoda; Nadeem R Abu-Rustum; Douglas A Levine; Matthew W Guile; Robert E Bristow; Carol Aghajanian; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2009-04-23       Impact factor: 5.482

9.  Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.

Authors:  Kristen Pepin; Amy Bregar; Michelle Davis; Alexander Melamed; Emily Hinchcliff; Allison Gockley; Neil Horowitz; Marcela G Del Carmen
Journal:  Gynecol Oncol       Date:  2017-10-04       Impact factor: 5.482

10.  Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness.

Authors:  Larissa A Meyer; Weiguo He; Charlotte C Sun; Hui Zhao; Alexi A Wright; Rudy S Suidan; Joseph Dottino; J Alejandro Rauh-Hain; Karen H Lu; Sharon H Giordano
Journal:  Gynecol Oncol       Date:  2018-06-29       Impact factor: 5.482

View more
  2 in total

Review 1.  Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.

Authors:  Mackenzie Cummings; Olivia Nicolais; Mark Shahin
Journal:  Diagnostics (Basel)       Date:  2022-04-14

2.  The surgical outcomes and perioperative complications of bowel resection as part of debulking surgery of advanced ovarian cancer patients.

Authors:  Shuang Ye; Yiyong Wang; Lei Chen; Xiaohua Wu; Huijuan Yang; Libing Xiang
Journal:  BMC Surg       Date:  2022-03-04       Impact factor: 2.102

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.